Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Woltering

Showing results (371-380 of 430) with videos related to

Pageof 43
Sort By:
Journal of the American College of Surgeons|January 16, 2017
Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single InstitutionEugene A Woltering, Brianne A Voros, David T Beyer, et al.
Pancreas|September 28, 2006
Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequencyEugene A Woltering, Ruth S Hilton, Christy M Zolfoghary, et al.
Pancreas|July 29, 2010
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)Alexandria T Phan, Kjell Oberg, Junsung Choi, et al.
Endocrinology and Metabolism Clinics of North America|February 26, 2011
Neuroendocrine tumors: current recommendations for diagnosis and surgical managementSaju Joseph, Yi-Zarn Wang, J Philip Boudreaux, et al.
Chemmedchem|December 7, 2007
Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIAThomas J Woltering, Geo Adam, Philipp Huguenin, et al.
Journal of Neuromuscular Diseases|March 4, 2025
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extensionAli A Habib, Artur Drużdż, Julian Grosskreutz, et al.
Regulatory Peptides|May 24, 2003
A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colonHelen J Cooke, Yu-Zhong Wang, Dawn Wray, et al.
Annals of Surgery|January 25, 2007
A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsyJason David Cundiff, Yi-Zarn Wang, Gregory Espenan, et al.
British Journal of Cancer|September 4, 2015
Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkersRuth Exner, Walter Pulverer, Martina Diem, et al.
Pancreas|July 29, 2010
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and CecumJ Philip Boudreaux, David S Klimstra, Manal M Hassan, et al.
Pageof 43

Showing results (371-380 of 430) with videos related to

Sort By:
Pageof 43
Journal of the American College of Surgeons|January 16, 2017
Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single InstitutionEugene A Woltering, Brianne A Voros, David T Beyer, et al.
Pancreas|September 28, 2006
Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequencyEugene A Woltering, Ruth S Hilton, Christy M Zolfoghary, et al.
Pancreas|July 29, 2010
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)Alexandria T Phan, Kjell Oberg, Junsung Choi, et al.
Endocrinology and Metabolism Clinics of North America|February 26, 2011
Neuroendocrine tumors: current recommendations for diagnosis and surgical managementSaju Joseph, Yi-Zarn Wang, J Philip Boudreaux, et al.
Chemmedchem|December 7, 2007
Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIAThomas J Woltering, Geo Adam, Philipp Huguenin, et al.
Journal of Neuromuscular Diseases|March 4, 2025
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extensionAli A Habib, Artur Drużdż, Julian Grosskreutz, et al.
Regulatory Peptides|May 24, 2003
A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colonHelen J Cooke, Yu-Zhong Wang, Dawn Wray, et al.
Annals of Surgery|January 25, 2007
A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsyJason David Cundiff, Yi-Zarn Wang, Gregory Espenan, et al.
British Journal of Cancer|September 4, 2015
Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkersRuth Exner, Walter Pulverer, Martina Diem, et al.
Pancreas|July 29, 2010
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and CecumJ Philip Boudreaux, David S Klimstra, Manal M Hassan, et al.
Pageof 43